- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Novocure Ltd (NVCR)
Novocure Ltd stock price live, this page displays NASDAQ NVCR stock exchange data. View the NVCR premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Novocure Ltd real time stock price chart below.
What Is the Novocure Ltd Stock Price Today?
The Novocure Ltd stock price today is 15.58.
What Is the Stock Symbol for Novocure Ltd?
The stock ticker symbol for Novocure Ltd is NVCR.
Is NVCR the Same as $NVCR?
$NVCR is a common way to refer to the Novocure Ltd ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Novocure Ltd Trade On?
Novocure Ltd is listed and trades on the NASDAQ stock exchange.
Is Novocure Ltd a Good Stock to Buy?
Determining whether Novocure Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Novocure Ltd share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NVCR quote. (ISIN: JE00BYSS4X48)
What Is the Novocure Ltd Stock Price Today?
The Novocure Ltd stock price today is 15.58.
What Is the Stock Symbol for Novocure Ltd?
The stock ticker symbol for Novocure Ltd is NVCR.
Is NVCR the Same as $NVCR?
$NVCR is a common way to refer to the Novocure Ltd ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Novocure Ltd Trade On?
Novocure Ltd is listed and trades on the NASDAQ stock exchange.
Is Novocure Ltd a Good Stock to Buy?
Determining whether Novocure Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Novocure Ltd share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NVCR quote. (ISIN: JE00BYSS4X48)
Currency in USD
15.58
-0.26(-1.61%)
Closed·
After Hours
15.580.00(0.00%)
·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
15.52
15.85
52 wk Range
11.70
34.13
NVCR Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected in 7 days
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
15.5215.85
52 wk Range
11.7034.13
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
NVCR Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
34.57
Upside
+121.90%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts do not anticipate the company will be profitable this year
Novocure Ltd Company Profile
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Novocure Ltd SWOT Analysis
Future Prospects | Delve into Novocure's product pipeline, including new arrays for lung cancer and anticipated FDA approvals, shaping its competitive edge |
Financial Performance | Analysts project 16.7% revenue growth for 2024, with price targets ranging from $24 to $40, despite current operational losses |
Market Expansion | Explore Novocure's strategic growth in Europe, particularly France, and potential opportunities in Italy and Spain's healthcare markets |
Innovative Cancer Tech | Novocure's Tumor Treating Fields therapy revolutionizes oncology, with promising applications beyond glioblastoma multiforme treatment |
Novocure Ltd Earnings Call Summary for Q4/2024
- Q4 revenue of $161M exceeded forecasts, up 21% YoY, despite EPS miss of -$0.61 vs -$0.36 expected
- Full year 2024 revenue reached $605M, a 19% increase, with strong international growth and $960M cash on hand
- Company expects low to mid-single digit growth in GBM business for 2025, with significant revenue ramp from lung cancer in 2026
- Novocure aims for positive adjusted EBITDA as new indication revenues materialize, expanding beyond single GBM focus
- Stock showed resilience with minor premarket decline; analysts maintain positive outlook despite ongoing profitability challenges
Last Updated: 02/27/2025, 09:12 AM
Read Full TranscriptCompare NVCR to Peers and Sector
Metrics to compare | NVCR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNVCRPeersSector | |
|---|---|---|---|---|
P/E Ratio | −10.3x | −5.2x | −0.5x | |
PEG Ratio | −0.54 | 0.00 | 0.00 | |
Price / Book | 4.8x | 2.5x | 2.6x | |
Price / LTM Sales | 2.9x | 3.1x | 2.9x | |
Upside (Analyst Target) | 108.5% | 80.7% | 68.1% | |
Fair Value Upside | Unlock | 3.4% | 10.4% | Unlock |
Analyst Ratings
5 Buy
2 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 34.57
(+121.90% Upside)
Earnings
Latest Release
Feb 27, 2025
EPS / Forecast
-0.61 / -0.36
Revenue / Forecast
161.26M / 153.04M
People Also Watch
FAQ
What Is the Novocure Ltd (NVCR) Stock Price Today?
The Novocure Ltd stock price today is 15.58
What Stock Exchange Does Novocure Ltd Trade On?
Novocure Ltd is listed and trades on the NASDAQ stock exchange.
What Is the Stock Symbol for Novocure Ltd?
The stock symbol for Novocure Ltd is "NVCR."
What Is the Novocure Ltd Market Cap?
As of today, Novocure Ltd market cap is 1.71B.
What is Novocure Ltd Earnings Per Share?
The Novocure Ltd EPS is -1.56.
What Is the Next Novocure Ltd Earnings Date?
Novocure Ltd will release its next earnings report on Apr 24, 2025.
From a Technical Analysis Perspective, Is NVCR a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.